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OVULATORY AND METABOLIC EFFECTS OF D- CHIRO-INOSITOL
IN THE POLYCYSTIC OVARY SYNDROME
JOHN E. NESTLER, M.D., DANIELA J. JAKUBOWICZ, M.D., PAULA REAMER, M.A., RONALD D. GUNN, M.S.,
AND GEOFFREY ALLAN, PH.D.

ABSTRACT
Background Women with the polycystic ovary syndrome have insulin resistance and hyperinsulinemia,
possibly because of a deficiency of a D-chiro-inositol–containing phosphoglycan that mediates the action of insulin. We hypothesized that the administration of D-chiro-inositol would replenish stores of the
mediator and improve insulin sensitivity.
Methods We measured steroids in serum and performed oral glucose-tolerance tests before and after
the oral administration of 1200 mg of D-chiro-inositol
or placebo once daily for six to eight weeks in 44
obese women with the polycystic ovary syndrome.
The serum progesterone concentration was measured weekly to monitor for ovulation.
Results In the 22 women given D-chiro-inositol,
the mean (±SD) area under the plasma insulin curve
after the oral administration of glucose decreased
from 13,417±11,572 to 5158±6714 µU per milliliter
per minute (81±69 to 31±40 nmol per liter per minute) (P=0.007; P=0.07 for the comparison of this
change with the change in the placebo group); glucose tolerance did not change significantly. The serum free testosterone concentration in these 22 women decreased from 1.1±0.8 to 0.5±0.5 ng per deciliter
(38±28 to 17±17 pmol per liter) (P=0.006 for the
comparison with the change in the placebo group).
The women’s diastolic and systolic blood pressure
decreased by 4 mm Hg (P<0.001 and P=0.05, respectively, for the comparisons with the changes in
the placebo group), and their plasma triglyceride concentrations decreased from 184±88 to 110±61 mg per
deciliter (2.1±0.2 to 1.2±0.1 mmol per liter) (P=0.002
for the comparison with the change in the placebo
group). None of these variables changed appreciably
in the placebo group. Nineteen of the 22 women who
received D-chiro-inositol ovulated, as compared with
6 of the 22 women in the placebo group (P<0.001).
Conclusions D-Chiro-inositol increases the action
of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory function and
decreasing serum androgen concentrations, blood
pressure, and plasma triglyceride concentrations.
(N Engl J Med 1999;340:1314-20.)
©1999, Massachusetts Medical Society.

I

NSULIN resistance and compensatory hyperinsulinemia, which can occur in otherwise normal persons, are risk factors for type 2 diabetes
mellitus,1-4 dyslipidemia,5-7 hypertension,5-7 and
atherosclerosis5 — a constellation of findings termed
syndrome X, or the metabolic syndrome.5 Both are
also prominent features of the polycystic ovary syndrome,8-10 a disorder characterized by chronic anovulation and hyperandrogenism that affects approximately 6 percent of women of reproductive age.11 In
these women, hyperinsulinemia both inhibits ovulation12 and stimulates ovarian testosterone production13,14; the women also have an increased incidence
of impaired glucose tolerance or type 2 diabetes mellitus10,15-17 and the other features of syndrome X.18-22
Some of the actions of insulin may involve lowmolecular-weight inositol phosphoglycan mediators.
When insulin binds to its receptor, mediators of this
class are generated by hydrolysis of glycosylphosphatidylinositol lipids located at the outer leaflet of
the cell membrane. Released mediators are then internalized and affect intracellular metabolic processes. Although different species have been identified, an
inositol phosphoglycan molecule containing D-chiroinositol and galactosamine is known to have a role
in activating key enzymes that control the oxidative
and nonoxidative metabolism of glucose.23
A deficiency of the D-chiro-inositol phosphoglycan mediator of the action of insulin may result in
resistance to insulin. Insulin resistance has been linked
to decreased urinary excretion of chiro-inositol (a
component of the putative D-chiro-inositol phosphoglycan mediator) in primates,24 in humans with
impaired glucose tolerance 25 or type 2 diabetes mellitus,26 and in nondiabetic first-degree relatives of
persons with diabetes.26 The amount of chiro-inositol in muscle is lower in subjects with type 2 diabetes mellitus than in normal subjects.27,28 In a study
of rats, administration of D-chiro-inositol decreased
hyperglycemia in rats with diabetes and improved
glucose tolerance in normal rats.29 In a study of
monkeys with varying degrees of insulin resistance,
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D -chiro-inositol

accelerated the disposal of glucose
and decreased insulin secretion.29 These observations
suggest that the administration of D-chiro-inositol,
which is then presumably used in the formation of
the active D-chiro-inositol phosphoglycan mediator,
may increase insulin sensitivity and improve the action of insulin in insulin-resistant subjects.
In this study we tested the hypothesis that D-chiroinositol, by virtue of its ability to increase sensitivity
to insulin, would have beneficial effects on ovulation
and ovarian production of androgens in women
with the polycystic ovary syndrome.

value exceeded 8 ng per milliliter (25 nmol per liter). They returned for the second study after six weeks, if they were confirmed to be in the follicular phase of the menstrual cycle by
measurement of a low serum progesterone value (<2.5 ng per
milliliter). All the studies performed at base line were repeated at
this visit. Four women in the D-chiro-inositol group and four
women in the placebo group had serum progesterone values in
the postovulatory range after six weeks and therefore continued
to receive the study treatment or placebo as assigned. Six of these
women were studied during week 7 and two women (both treated with D-chiro-inositol) were studied during week 8, when their
serum progesterone concentrations were low. No side effects
were noted in the women in either group.

METHODS

After base-line blood samples had been obtained at 4 p.m., leuprolide (Lupron, Abbott, Takeda, Japan) was administered subcutaneously at a dose of 10 µg per kilogram of body weight.
Blood samples were collected 0.5, 1, 16, 20, and 24 hours after
leuprolide administration for measurement of serum luteinizing
hormone and 17a-hydroxyprogesterone concentrations. The women ate an evening meal but subsequently fasted until completion
of the test. The average of the serum luteinizing hormone concentrations in the blood samples obtained after 0.5 and 1 hour
was considered the early serum luteinizing hormone response,
and the average of the values at 16, 20, and 24 hours was considered the late serum luteinizing hormone response. The serum
17a-hydroxyprogesterone concentration at 0 hours was the basal
value, and the highest serum 17a-hydroxyprogesterone value after leuprolide administration was considered the peak value.

Subjects
We studied 44 women, 18 to 40 years of age, with the polycystic ovary syndrome, indicated by the presence of oligomenorrhea (eight or fewer menstrual periods in the previous year) and
hyperandrogenism (high serum concentrations of free testosterone or hirsutism). They were recruited from the Hospital de
Clinicas Caracas in Caracas, Venezuela. Other inclusion criteria
were obesity, defined as a body-mass index (the weight in kilograms divided by the square of the height in meters) of more than
28, normal results on thyroid-function tests, and normal serum
prolactin concentrations. Ultrasonography of the ovaries revealed
polycystic ovaries in all the women,30 but this condition was not
an inclusion criterion. None of the women had diabetes mellitus,
but 10 had impaired glucose tolerance, defined as a serum glucose concentration of at least 140 but less than 200 mg per deciliter (7.8 to 11.2 mmol per liter) two hours after the oral administration of 75 g of glucose.31 None had taken any medications
for at least two months. Thirty-two of the women were white,
seven Hispanic, two Afro-Hispanic, two Arabic, and one Asian; four
women had one child each, and the remainder had no children.
Twenty-two women were randomly assigned to receive D-chiroinositol (INS-1, Insmed Pharmaceuticals, Richmond, Va.) and 22
to receive placebo in a double-blind trial. The randomization
schedule was generated in blocks of four, and the drug and placebo were packaged at the same time and labeled according to
subject number. The study was approved by the institutional review boards of the Hospital de Clinicas Caracas and Virginia
Commonwealth University, and each woman gave written informed
consent.
Design of the Study
At the time of entry into the study, all the women were in the
equivalent of the follicular phase of the menstrual cycle, as documented by a serum progesterone concentration below 2.5 ng per
milliliter (8.0 nmol per liter). The women came to the hospital
after a 12-hour overnight fast, at which time their weight, height,
waist-to-hip ratio, and blood pressure while supine were measured. Blood samples were drawn at 8:30, 8:45, and 9 a.m., and
equal volumes of serum were pooled for the measurement of serum steroids and sex hormone–binding globulin. At 9 a.m., 75 g
of dextrose (Glycolab, Relab Laboratory, Caracas, Venezuela) was
given orally. Blood samples were collected after 30, 60, 90, and
120 minutes for the measurement of plasma glucose and insulin.
The women ate a light meal after the oral glucose-tolerance test
and returned for a leuprolide stimulation test at 4 p.m. (described
below). After this test, the women began to take 1200 mg of
D -chiro-inositol or placebo orally once daily. They were instructed
not to alter their usual eating habits, physical activity, or lifestyle
during the study; they were also advised to refrain from sexual
intercourse or to use a barrier method of contraception.
The women returned weekly for measurements of serum progesterone, and ovulation was presumed to have occurred if the

Leuprolide Stimulation Test

Assays
Blood samples were centrifuged as soon as they were obtained,
and the serum or plasma was stored at ¡20°C until assayed. The
plasma or serum hormones and sex hormone–binding globulin
(measured as protein) were assayed as previously described.12
The serum free testosterone concentration was calculated according to the method of Sodergard et al.32 with use of the simultaneously measured serum albumin concentration. To avoid
variation between assays, all the samples from an individual
woman were analyzed in duplicate in a single assay for each hormone. The intraassay coefficient of variation was 5.5 percent for
the plasma insulin assay, 1.6 percent for the serum luteinizing
hormone assay, and less than 10 percent for all serum steroid
hormone assays.
Plasma concentrations of cholesterol and triglycerides were
measured at the Hospital de Clinicas Caracas, and plasma concentrations of high-density lipoprotein and low-density lipoprotein
cholesterol were measured by Penn Medical (Washington, D.C.).
Statistical Analysis
The results are reported as means ±SD. Fisher’s exact test was
used to analyze the differences in ovulation rates between the
women who received D-chiro-inositol and those who received placebo. For the other variables, the results were analyzed by comparing the changes in values from base line to the end of the study
in the D-chiro-inositol group with the corresponding changes in
the placebo group. We tested the distribution of the changes in
the two groups for normality with the Wilk–Shapiro test and then
compared the changes with use of Student’s two-tailed unpaired
t-test or the Mann–Whitney rank-sum test. For differences between the groups that were of borderline significance, we also report the within-group comparisons, which were analyzed by Student’s two-tailed paired t-test or the Wilcoxon signed-rank test.
The responses of plasma glucose and insulin to the oral administration of glucose and the responses of serum luteinizing hormone and 17a-hydroxyprogesterone after the administration of
leuprolide were analyzed by calculating the areas under the response curves by the trapezoidal rule.
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RESULTS
Base-Line Characteristics

The base-line clinical and biochemical characteristics of the women in the D-chiro-inositol and placebo groups were similar (Table 1 and Fig. 1 and 2).
Six women in the D-chiro-inositol group had impaired glucose tolerance, as did four women in the
placebo group.
Anthropometric Measurements and Plasma Lipid
Concentrations

The body-mass index did not change in either
group during the study, but the change in the waistto-hip ratio in the D-chiro-inositol group was significantly different from that in the placebo group
(P<0.001). In the D-chiro-inositol group, both the
decrease in diastolic blood pressure, from 89±5 to
85±6 mm Hg, and the decrease in systolic blood
pressure, from 130±7 to 126±7 mm Hg, differed
significantly from the corresponding changes in the
placebo group (P<0.001 and P=0.05, respectively).
In the D-chiro-inositol group, the plasma total
cholesterol concentration decreased significantly (P=
0.03), but this decrease did not differ significantly
from the slight increase in the placebo group (P=
0.08) (Table 1). In contrast, the decrease in the plasma triglyceride concentration in the D-chiro-inositol
group was significantly greater than that in the placebo group (P=0.002) (Table 1). Plasma high-density and low-density lipoprotein cholesterol concentrations did not change significantly in either group.
Plasma Insulin and Glucose Profiles

There was no statistically significant difference between the decrease in the plasma insulin concentration during fasting in the D-chiro-inositol group and
the small increase in the placebo group (Table 1). In
the D-chiro-inositol group, the area under the plasma insulin curve after oral glucose administration
decreased from 13,417±11,572 to 5158±6714 µU
per milliliter per minute (81±69 to 31±40 nmol per
liter per minute) (P=0.007), but this decrease did
not differ significantly from that in the placebo group
(P=0.07).
The plasma glucose concentration during fasting
and the area under the plasma glucose curve did not
change significantly in either the D-chiro-inositol or
the placebo group. However, when the women with
impaired glucose tolerance at base line were analyzed separately, the area under the plasma glucose
curve decreased from 13,983±3625 to 10,945±2410
mg per deciliter per minute (783±203 to 613±135
mmol per liter per minute) in the D-chiro-inositol
group (P=0.03), resulting in normal glucose-tolerance curves in these six women but did not
change substantially in four women with impaired
glucose tolerance in the placebo group (15,334±
1316 ·

1446 vs. 13,920±1272 mg per deciliter per minute
[859±81 vs. 780±71 mmol per liter per minute])
(P=0.18).
Responses of Serum Luteinizing Hormone to Leuprolide

Changes in basal concentrations of serum luteinizing hormone did not differ between the D-chiroinositol and placebo groups. In contrast, the decrease in the early response of serum luteinizing
hormone to leuprolide in the D-chiro-inositol group,
from 66±55 mIU per milliliter at base line to
30±15 mIU per milliliter after six to eight weeks of
treatment, differed significantly from the change in
the placebo group (P=0.05) (Fig. 1). Similarly, the
decrease in the late response of serum luteinizing
hormone to leuprolide in the D-chiro-inositol group,
from 103±83 mIU per milliliter at base line to
49±29 mIU per milliliter at six to eight weeks, differed significantly from that in the placebo group
(P=0.04).
Responses of Serum 17a-Hydroxyprogesterone
to Leuprolide

The mean basal serum 17a-hydroxyprogesterone
concentration did not change significantly with treatment in either the D-chiro-inositol or the placebo
group (Fig. 2). In the D-chiro-inositol group, the decrease in the peak serum 17a-hydroxyprogesterone
concentration after the administration of leuprolide,
from 319±212 ng per deciliter at base line to
183±117 ng per deciliter after six to eight weeks
(9.6±6.4 to 5.5±3.5 nmol per liter), differed significantly from that in the placebo group (P=0.05).
The area under the serum 17a-hydroxyprogesterone
curve also decreased, from 5538±3304 to 3103±
1765 ng per deciliter per hour (167±100 to 94±53
nmol per liter per hour), in the D-chiro-inositol
group (P=0.006), but this change did not differ significantly from that in the placebo group (P=0.07).
Serum Sex-Steroid Concentrations

The administration of D-chiro-inositol was associated with a decrease in the serum testosterone concentration and an increase in the serum sex hormone–binding globulin concentration (Table 1); both
changes differed significantly from those in the placebo group (P=0.003 for both comparisons). This
change resulted in a 55 percent decrease in the serum free testosterone concentration in the D-chiroinositol group, from 1.1±0.8 to 0.5±0.5 ng per
deciliter (38±28 to 17±17 pmol per liter), which
differed significantly from that in the placebo group
(P=0.006). The 47 percent decrease in serum dehydroepiandrosterone sulfate in the D-chiro-inositol
group differed significantly from that in the placebo
group (P=0.001) (Table 1). The serum concentrations of the other steroids did not change substantially in either group.
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TABLE 1. CHARACTERISTICS OF 44 WOMEN WITH THE POLYCYSTIC OVARY SYNDROME AT BASE LINE
ADMINISTRATION OF D-CHIRO-INOSITOL OR PLACEBO FOR SIX TO EIGHT WEEKS.*
CHARACTERISTIC

D -CHIRO-INOSITOL

GROUP (N=22)

AND AFTER THE

PLACEBO GROUP (N=22)

AFTER D-CHIROBASE LINE

Age (yr)
Body-mass index
Waist-to-hip ratio
Blood pressure (mm Hg)
Systolic
Diastolic
Plasma cholesterol (mg/dl)
Total
High-density lipoprotein
Low-density lipoprotein
Plasma triglycerides (mg/dl)
Plasma insulin during fasting (µU/ml)
Area under the plasma insulin curve (µU/ml/min)
Plasma glucose during fasting (mg/dl)
Area under the plasma glucose curve (mg/dl/min)
Serum progesterone (ng/ml)
Serum testosterone (ng/dl)
Serum free testosterone (ng/dl)
Serum androstenedione (ng/dl)
Serum 17b-estradiol (ng/dl)
Serum dehydroepiandrosterone sulfate (µg/dl)
Serum sex hormone–binding globulin (µg/dl)

INOSITOL

BASE LINE

AFTER PLACEBO

29±6
31.3±2.4
0.86±0.05

—
31.5±2.4
0.84±0.06†

26±5
31.0±2.2
0.84±0.08

—
31.0±2.2
0.85±0.08

130±7
89±5

126±7‡
85±6†

131±13
87±6

128±6
89±5

192±58§
38±8
124±7
110±61¶
22±21
5158±6714¿
90±19
12,656±4316
0.6±0.2
61±33**
0.5±0.5††
173±50
8.9±4.4
274±91‡‡
4.8±2.2**

200±36
36±9
127±35
136±71
38±51
11,371±8027
95±21
14,115±2462
0.8±0.4
80±43
0.8±0.4
180±51
9.6±4.1
459±177
2.6±0.9

201±39
38±8
126±27
130±63
42±52
9210±7840
95±24
14,014±3089
0.7±0.2
79±39
0.8±0.4
186±53
10.8±9.4
421±179
2.8±0.9

209±45
36±11
124±36
184±88
35±40
13,417±11,572
86±12
13,796±2591
0.7±0.4
90±47
1.1±0.8
201±69
8.8±4.0
519±229
2.5±1.0

*Values are means ±SD. To convert the values for cholesterol to millimoles per liter, multiply by 0.026. To convert the values for triglycerides to millimoles per liter, multiply by 0.11. To convert the values for insulin to picomoles per liter, multiply by 6.0. To convert the values
for glucose to millimoles per liter, multiply by 0.056. To convert the values for progesterone to nanomoles per liter, multiply by 3.18. To
convert the values for testosterone to picomoles per liter, multiply by 34.7. To convert the values for androstenedione to picomoles per liter,
multiply by 34.9. To convert the values for 17b-estradiol to picomoles per liter, multiply by 36.7. To convert the values for dehydroepiandrosterone sulfate to micromoles per liter, multiply by 0.027. To convert the values for sex hormone–binding globulin to nanomoles per liter,
multiply by 34.7.
†P<0.001 for the comparison with the change in the placebo group.
‡P=0.05 for the comparison with the change in the placebo group.
§P=0.03 for the comparison with the base-line value in the D-chiro-inositol group, and P=0.08 for the comparison with the change in
the placebo group.
¶P=0.002 for the comparison with the change in the placebo group.
¿P=0.007 for the comparison with the base-line value in the D-chiro-inositol group, and P=0.07 for the comparison with the change in
the placebo group.
**P=0.003 for the comparison with the change in the placebo group.
††P=0.006 for the comparison with the change in the placebo group.
‡‡P=0.001 for the comparison with the change in the placebo group.

DISCUSSION

Ovulation

Nineteen of the 22 women in the D-chiro-inositol
group (86 percent) ovulated during treatment with
D -chiro-inositol, as compared with only 6 of the 22
women (27 percent) in the placebo group (P<0.001).
The mean peak serum progesterone concentration
in the 19 women in the D-chiro-inositol group who
ovulated was 12.4±1.7 ng per milliliter (39.4±5.4
nmol per liter). Figure 3 shows the number of women in the D-chiro-inositol and placebo groups who
had serum progesterone concentrations that exceeded 8 ng per milliliter (indicative of ovulation) in
weeks 2 through 8.

In nonhuman primates 24 and in humans,25-28 insulin resistance may be related to a deficiency in a
putative D-chiro-inositol–containing phosphoglycan
mediator of insulin action. The aim of this study was
to determine whether the oral administration of
D-chiro-inositol would improve insulin sensitivity in
a group of insulin-resistant women with the polycystic ovary syndrome. The polycystic ovary syndrome
was selected as the model for insulin resistance because it is known that increasing insulin sensitivity in
women with this disorder results in improved ovulatory function and decreased serum androgen conVol ume 340
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Figure 1. Serum Luteinizing Hormone Concentrations in Women with the Polycystic Ovary Syndrome at Base Line and after
the Administration of D-Chiro-Inositol or Placebo for Six to
Eight Weeks.
Serum luteinizing hormone was measured before and early
and late after stimulation with leuprolide (10 µg per kilogram).
Values are means ±SD. The asterisk indicates P=0.05 for the
comparison of the change in the D-chiro-inositol group with the
change in the placebo group. The dagger indicates P=0.04 for
the comparison of the change in the D-chiro-inositol group with
the change in the placebo group.
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Figure 2. Serum 17a-Hydroxyprogesterone Concentrations in
Women with the Polycystic Ovary Syndrome at Base Line and
after the Administration of D-Chiro-Inositol or Placebo for Six
to Eight Weeks.
Serum 17a-hydroxyprogesterone was measured before and after stimulation with leuprolide (10 µg per kilogram). Values are
means ¡SD. To convert the values for 17a-hydroxyprogesterone to picomoles per liter, multiply by 30.2. The asterisk indicates P=0.05 for the comparison of the change in the D-chiroinositol group with the change in the placebo group. The
dagger indicates P=0.006 for the comparison with the baseline value in the D-chiro-inositol group, and P=0.07 for the
comparison of the change in the D-chiro-inositol group with
the change in the placebo group. AUC denotes area under the
curve.
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;
;
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Because of technical obstacles, it has not been
possible to determine whether the skeletal muscles
of women with the polycystic ovary syndrome are
deficient in the putative D-chiro-inositol phosphoglycan mediator, but evidence suggests that this is
the case in patients with type 2 diabetes mellitus.27,28
A deficiency in this mediator could result from a
defect in an epimerase-type enzyme responsible for
the intracellular conversion of myo-inositol to chiroinositol40,41 or, alternatively, from accelerated catabolism of D-chiro-inositol before renal filtration. If either was the case, then exogenous administration of
D-chiro-inositol would replenish diminished intracellular D-chiro-inositol stores and restore the D-chiroinositol phosphoglycan content in skeletal muscle
and other insulin target tissues to normal levels.
We conclude that D-chiro-inositol improves ovulatory function and several metabolic abnormalities related to insulin resistance in women with the polycystic ovary syndrome. These observations also suggest
that D-chiro-inositol could be used to treat the polycystic ovary syndrome and that D-chiro-inositol may
prove useful in the treatment of other disorders that
are pathophysiologically related to insulin resistance.
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Figure 3. Number of Women with the Polycystic Ovary Syndrome Who Ovulated during the Administration of D-ChiroInositol or Placebo for Six to Eight Weeks.
Ovulation was indicated by a serum progesterone concentration greater than 8 ng per milliliter. After eight weeks, 19 women in the D-chiro-inositol group had ovulated, as compared
with only 6 women in the placebo group (P<0.001).

centrations.12-14 Moreover, the polycystic ovary syndrome is associated with several other metabolic
abnormalities that are also probably linked to insulin
resistance; they include glucose intolerance,10,15-17
dyslipidemia,20-22 and hypertension.18,20
We found that the administration of D-chiro-inositol to women with the polycystic ovary syndrome
decreased the insulin response to orally administered
glucose. Although its cause was not assessed directly
in our study, this decrease was most likely due to an
improvement in peripheral insulin sensitivity.24-26,28,29
In the women who had impaired glucose tolerance
at base line, glucose tolerance improved. Simultaneously with the reduction in insulin secretion, women
who received D-chiro-inositol had a striking improvement in ovulatory function: 86 percent of these
women ovulated, as compared with only 27 percent
of the women who received placebo. Serum androgen concentrations also decreased in the women who
received D-chiro-inositol, as did ovarian androgen production, as reflected by a decreased 17a-hydroxyprogesterone response to leuprolide. These findings
are consistent with an improvement in insulin sensitivity, as demonstrated previously with drugs such as
metformin12,14,33-37 and troglitazone.38,39 The women
who received D-chiro-inositol also had decreases in
both systolic and diastolic blood pressure and plasma triglyceride concentrations.
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